This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Tel Aviv University, Thomas Jefferson University. Active years: 2020-2022.
Company Filing History:
2 out of 840 
1 out of 536 
Years Active: 2020-2022
Title: Nir Ben-Tal: Innovator in Antiviral Research
Introduction
Nir Ben-Tal is a prominent inventor based in Tel Aviv, Israel. He has made significant contributions to the field of antiviral research, particularly in developing therapeutic agents for drug-resistant influenza A. With a total of 2 patents, his work is crucial in addressing the challenges posed by resistant strains of the virus.
Latest Patents
Ben-Tal's latest patents include innovative antiviral agents designed to combat amantadine-resistant influenza A. The first patent details an effective therapeutic agent for the M2 channel, comprising sulfonylamide or oxabicyclo structures. This agent is specifically effective for treating infections caused by amantadine-resistant influenza A. The second patent similarly focuses on antiviral agents for amantadine-resistant influenza A, outlining methods of treatment through the administration of these agents.
Career Highlights
Throughout his career, Nir Ben-Tal has worked with notable institutions such as Ramot at Tel Aviv University Ltd. and Thomas Jefferson University. His research has been instrumental in advancing the understanding and treatment of influenza A infections.
Collaborations
Some of his notable coworkers include Roger S. Armen and Laurence C. Eisenlohr. Their collaborative efforts have contributed to the success of his research initiatives.
Conclusion
Nir Ben-Tal's innovative work in antiviral research highlights the importance of developing effective treatments for drug-resistant infections. His contributions are vital in the ongoing battle against influenza A, showcasing the impact of dedicated research in the field of medicine.